Current insights into the treatments of severe aplastic anemia in China

Current insights into the treatments of severe aplastic anemia in China

Recently, several studies have been conducted to generate considerable evidence regarding unique treatments for severe aplastic anemia (SAA) in China. Haploidentical donor hematopoietic stem cell transplantation (HID-HSCT) showed an overall survival rate (80.3–86.1%) comparable to those with immunos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of hematology 2020-09, Vol.112 (3), p.292-299
Hauptverfasser: Ye, Lei, Zhang, Fengkui, Kojima, Seiji
Format: Artikel
Sprache:eng
Schlagworte:
Anemia
Aplastic anemia
Bone marrow
Bone marrow transplantation
Hematology
Hematopoietic stem cells
Immunoglobulins
Immunosuppressive agents
Lymphocytes
Medicine
Medicine & Public Health
Mesenchymal stem cells
Mesenchyme
Mud
Oncology
Review Article
Stem cell transplantation
Stem cells
Stromal cells
Survival
Transplantation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Recently, several studies have been conducted to generate considerable evidence regarding unique treatments for severe aplastic anemia (SAA) in China. Haploidentical donor hematopoietic stem cell transplantation (HID-HSCT) showed an overall survival rate (80.3–86.1%) comparable to those with immunosuppressive therapy (IST) and matched related donor (MRD)- and matched unrelated donor (MUD)-HSCT. Failure-free survival of HID-HSCT was also comparable (76.4–85.0%) to those of MRD- and MUD-HSCT and better than IST in patients 
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-020-02955-1